Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 9/20 | 0.59 |
| ▸ | THRA | P10827 | 3/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041996 | 0.86 | ALDH1A1 (0.50) | THRBTHRASCN9AALDH1A1GAA | |
| SCHEMBL3231771 | 0.79 | THRB (0.55) | THRBTHRAHSP90AA1ALDH1A1GAA | |
| SCHEMBL5332095 | 0.77 | THRB (0.63) | THRBTHRAHSP90AA1ALDH1A1GAA | |
| SCHEMBL7040403 | 0.77 | THRB (0.57) | THRBTHRAHSP90AA1ALDH1A1GAA | |
| SCHEMBL7037496 | 0.76 | THRB (0.58) | THRBTHRAALDH1A1POLBTSHR | |
| SCHEMBL7042657 | 0.75 | THRB (0.56) | THRBTHRAHSP90AA1ALDH1A1GAA | |
| SCHEMBL6657695 | 0.75 | THRB (0.55) | THRBTHRAHSP90AA1 | |
| SCHEMBL6663395 | 0.75 | THRB (0.55) | THRBTHRAHSP90AA1 | |
| SCHEMBL6658310 | 0.75 | THRB (0.55) | THRBTHRAHSP90AA1 | |
| SCHEMBL23691219 | 0.74 | THRB (0.75) | THRBTHRAHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040535-A1 | Tetrazole compounds as thyroid receptor ligands | ASPNES GARY E (US) | 2003-02-27 | — | — | US | disclosed |
| US-6441015-B2 | OBESITY, ANTIDIABETIC AGENTS, CARDIOVASCULAR DISORDERS | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | PFIZER INC. | 2002-01-17 | — | — | US | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040535-A1 | Tetrazole compounds as thyroid receptor ligands | THRA, TSHR, THRB | THRB 3/4885THRA 1/4885HSP90AA1 3917/4885 |
| US-20020006946-A1 | Tetrazole compounds as thyroid receptor ligands | TSHR, THRA, THRB | THRB 3/4885THRA 2/4885HSP90AA1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.